Bristol Myers Squibb's RYZ101 meets Phase 3 ACTION-1 primary endpoint in neuroendocrine tumour trial

Bristol Myers Squibb announced topline results from RayzeBio's planned interim analysis of the ACTION-1 trial: RYZ101 met its primary endpoint with a statistically significant and clinically meaningful improvement in progression-free survival by blinded independent central review, with safety consistent with the known profile.

Detected & updated continuously · Source: Nebula